Olix Pharmaceuticalsinc Stock Gross Profit

226950 Stock   20,900  200.00  0.95%   
OliX PharmaceuticalsInc fundamentals help investors to digest information that contributes to OliX PharmaceuticalsI's financial success or failures. It also enables traders to predict the movement of OliX Stock. The fundamental analysis module provides a way to measure OliX PharmaceuticalsI's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to OliX PharmaceuticalsI stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

OliX PharmaceuticalsInc Company Gross Profit Analysis

OliX PharmaceuticalsI's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Gross Profit

 = 

Revenue

-

Cost of Revenue

More About Gross Profit | All Equity Analysis

Current OliX PharmaceuticalsI Gross Profit

    
  2.42 B  
Most of OliX PharmaceuticalsI's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, OliX PharmaceuticalsInc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Competition

According to the company disclosure, OliX PharmaceuticalsInc reported 2.42 B of gross profit. This is 7.69% higher than that of the Healthcare sector and 154.12% higher than that of the Biotechnology industry. The gross profit for all Republic of Korea stocks is 91.18% higher than that of the company.

OliX Gross Profit Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses OliX PharmaceuticalsI's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of OliX PharmaceuticalsI could also be used in its relative valuation, which is a method of valuing OliX PharmaceuticalsI by comparing valuation metrics of similar companies.
OliX PharmaceuticalsI is currently under evaluation in gross profit category among its peers.

OliX Fundamentals

About OliX PharmaceuticalsI Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze OliX PharmaceuticalsInc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OliX PharmaceuticalsI using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OliX PharmaceuticalsInc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Other Information on Investing in OliX Stock

OliX PharmaceuticalsI financial ratios help investors to determine whether OliX Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in OliX with respect to the benefits of owning OliX PharmaceuticalsI security.